Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Odontocide is a patented endodontic intracanal dressing developed by Australian Dental Manufacturing (ADM). It is a combination product consisting of 20% calcium hydroxide and 7% ibuprofen. The calcium hydroxide component achieves a high pH (over 12), which provides a potent antibacterial effect against bacteria and biofilms within the root canal system. The ibuprofen component acts as a non-selective cyclooxygenase (COX) inhibitor, functioning as a non-steroidal anti-inflammatory drug (NSAID) to reduce post-operative sensitivity and interappointment pain. The product is typically used as a temporary dressing during endodontic treatment for patients suffering from apical periodontitis or pulpal inflammation. It is TGA-certified in Australia and supplied as a paste in an 8-gram tube.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on odontocide.